Stam et al. report on the placebo-controlled, double-blind, cross-over trial in 35 patients with spinal muscular atrophy types 2–4 to investigate the safety and efficacy of fatigability and motor function of the acetylcholinesterase inhibitor pyridostigmine. This evidence concerns the gene ACHE and spinal muscular atrophy, type II.